OMGA News and Press, Omega Therapeutics Inc. From 06/27/22

Gainers: NeuroSense Therapeutics NRSN +83%. Axsome Therapeutics (AXSM) +37%. Agile Therapeutics (AGRX) +31%. GreenLight Biosciences (GRNA) +26%. Femasys (FEMY) +11%. Losers: GeoVax Labs GOVX -14%. SIGA Technologies (SIGA) -14%. Eargo (EAR) -12%. BioAtla...

Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer PR Newswire CAMBRIDGE, Mass. , June 23,...

Omega Therapeutics (NASDAQ:OMGA) submitted an investigational new drug application to the U.S. Food and Drug Administration (FDA) to get clearance to start a clinical trial of its lead product candidate OTX-2002 for treating a type of liver cancer called hepatocellular carcinoma. "This also m...

Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma PR Newswire Investigational New Drug Application Submitted by Omega Represents the First Epigenomic Con...

Gainers: Aero Clean Technologies AERC +49%. Houston American Energy (HUSA) +37%. Jan One JAN +37%. Oncorus (ONCR) +41%. Cytosorbents  (CTSO) +33%. Mirati Therapeutics MRTX +30%. Omega (OMGA) +27%. Codiak BioSciences (CDAK) +27%. Quantum Computing (QUBT) +26%. GitLab GTLB&#...

Omega Therapeutics to Participate in the Jefferies Healthcare Conference and Goldman Sachs 43rd Annual Global Healthcare Conference in June 2022 PR Newswire CAMBRIDGE, Mass. , June 2, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"),...

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

The following slide deck was published by Omega Therapeutics, Inc. in conjunction with this event. For further details see: Omega Therapeutics (OMGA) Investor Presentation - Slideshow

Omega Therapeutics press release (NASDAQ:OMGA): Q1 GAAP EPS of -$0.42 beats by $0.15. Revenue of $0.27M. For further details see: Omega Therapeutics GAAP EPS of -$0.42 beats by $0.15, revenue of $0.27M

Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire Investigational New Drug Application for OTX-2002 for MYC Driven Hepatocellular Carcinoma on Track to be Submitted in the First Half of 2022 ...